Baldini E - Search Results

1

Cyclin A and E2F1 overexpression correlate with reduced disease-free survival in node-negative breast cancer patients.

Baldini E, Camerini A, Sgambato A, Prochilo T, Capodanno A, Pasqualetti F, Orlandini C, Resta L, Bevilacqua G, Collecchi P. Baldini E, et al. Anticancer Res. 2006 Nov-Dec;26(6B):4415-21. Anticancer Res. 2006. PMID: 17201163 Free article.

2

Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).

Baldini E, Ardizzoni A, Prochilo T, Cafferata MA, Boni L, Tibaldi C. Baldini E, et al. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S25-8. doi: 10.1007/s00280-002-0449-z. Epub 2002 Apr 17. Cancer Chemother Pharmacol. 2002. PMID: 12042986 Review.

3

[The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?].

Baldini E, Prochilo T. Baldini E, et al. Suppl Tumori. 2004 Jul-Aug;3(4):S79-80. Suppl Tumori. 2004. PMID: 15206221 Review. Italian. No abstract available.

4

Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.

Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Conte PF, et al. Among authors: baldini e. Cancer. 2004 Aug 15;101(4):704-12. doi: 10.1002/cncr.20400. Cancer. 2004. PMID: 15305399 Free article. Clinical Trial.

5

Long-term results of combined-modality therapy for inflammatory breast carcinoma.

Baldini E, Gardin G, Evagelista G, Prochilo T, Collecchi P, Lionetto R. Baldini E, et al. Clin Breast Cancer. 2004 Dec;5(5):358-63. doi: 10.3816/cbc.2004.n.042. Clin Breast Cancer. 2004. PMID: 15585073

6

Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma.

Capodanno A, Camerini A, Orlandini C, Baldini E, Resta ML, Bevilacqua G, Collecchi P. Capodanno A, et al. Among authors: baldini e. Hum Pathol. 2009 Oct;40(10):1408-17. doi: 10.1016/j.humpath.2009.02.005. Epub 2009 May 9. Hum Pathol. 2009. PMID: 19428048

7

Benefit from a high dose of gefitinib in a woman with lung adenocarcinoma and an epidermal growth factor receptor tyrosine-kinase acquired mutation.

Baldini E, Prochilo T, Boldrini L, Melfi F, Fontanini G. Baldini E, et al. Mol Med Rep. 2008 Jan-Feb;1(1):41-3. Mol Med Rep. 2008. PMID: 21479375

8

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

Vici P, Pizzuti L, Sperduti I, Frassoldati A, Natoli C, Gamucci T, Tomao S, Michelotti A, Moscetti L, Gori S, Baldini E, Giotta F, Cassano A, Santini D, Giannarelli D, Di Lauro L, Corsi DC, Marchetti P, Sini V, Sergi D, Barba M, Maugeri-Saccà M, Russillo M, Mentuccia L, D'Onofrio L, Iezzi L, Scinto AF, Da Ros L, Bertolini I, Basile ML, Rossi V, De Maria R, Montemurro F. Vici P, et al. Among authors: baldini e. Oncotarget. 2016 Apr 5;7(14):17932-44. doi: 10.18632/oncotarget.7480. Oncotarget. 2016. PMID: 26910921 Free PMC article.

9

Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.

Tibaldi C, Camerini A, Tiseo M, Mazzoni F, Barbieri F, Vittimberga I, Brighenti M, Boni L, Baldini E, Gilli A, Honeywell R, Chartoire M, Peters GJ, Giovannetti E; Italian Oncological Group of Clinical Research (GOIRC). Tibaldi C, et al. Among authors: baldini e. Br J Cancer. 2018 Nov;119(11):1326-1331. doi: 10.1038/s41416-018-0307-3. Epub 2018 Nov 8. Br J Cancer. 2018. PMID: 30405211 Free PMC article.

10

Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.

Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Caparello C, Turrini M, Rossi V, Ciccone LP, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E. Tibaldi C, et al. Among authors: baldini e. Anticancer Agents Med Chem. 2022;22(7):1278-1285. doi: 10.2174/1871520621666210727112212. Anticancer Agents Med Chem. 2022. PMID: 34315390

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters